Shanghai Shyndec Pharmaceutical Co., Ltd., commonly referred to as Shyndec, is a prominent player in the pharmaceutical industry, headquartered in Shanghai, China. Established in 1995, the company has made significant strides in the development and manufacturing of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms, catering to both domestic and international markets. With a strong focus on research and development, Shyndec offers a diverse portfolio of products, including generic drugs and innovative formulations. Their commitment to quality and compliance with international standards has positioned them as a trusted partner in the pharmaceutical supply chain. Notable achievements include successful collaborations with global pharmaceutical companies, enhancing their reputation as a reliable source of pharmaceutical solutions.
How does Shanghai Shyndec Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Shanghai Shyndec Pharmaceutical Co., Ltd.'s score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shanghai Shyndec Pharmaceutical Co., Ltd., headquartered in CN, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. Consequently, there are no recorded Scope 1, Scope 2, or Scope 3 emissions totals available for analysis. Additionally, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments towards carbon reduction initiatives at this time. Without specific emissions data or reduction strategies, it is challenging to assess their climate impact or commitments within the pharmaceutical industry context. As the company does not inherit emissions data from a parent organization, all information is based solely on their own reporting. Further transparency and commitment to climate action would be beneficial for understanding their environmental footprint and aligning with industry standards.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shanghai Shyndec Pharmaceutical Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

